When pills are no longer enough
REALIZE THE POTENTIAL WITH OZEMPIC®
Ozempic®—the only type 2 diabetes treatment with greater A1C and weight results vs Trulicity®, and study-titrated Lantus® and as an add-on to basal insulin1,2
Pen shown delivers doses of
0.25 mg or 0.5 mg.
aMajor adverse CV events (MACE)=CV death, nonfatal MI, or nonfatal stroke
bWeight change as a secondary endpoint in clinical trials.
cResults apply to Ozempic® plus standard of care vs standard of care alone in SUSTAIN 6 trial for patients with T2D and established CVD.
T2D=type 2 diabetes; CVD=cardiovascular disease; CVOT=cardiovascular outcomes trial; CV=cardiovascular; MI=myocardial infarction.
Resources for starting patients
Find quick links to all the resources you need to start your patients on Ozempic®